Table 1.
Sample characteristics
| Training set | Test set | Extra Validation set | ||||
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||||
| Total | 84 | 100% | 72 | 100% | 69 | 100% |
| Patient series | ||||||
| Clinical genetics centre | 34 | 40% | 18 | 25% | ||
| Neoadjuvant series | 50 | 60% | 8 | 11% | ||
| Randomised controlled trial series | 0 | 0% | 46 | 64% | ||
| Subtype | ||||||
| HER2+ | 11 | 13% | 5 | 7% | 0 | 0% |
| ER+HER2- | 22 | 26% | 10 | 14% | 0 | 0% |
| Triple-negative (TN) | 52 | 61% | 57 | 79% | 69 | 100% |
| ER expression | ||||||
| Negative | 57 | 67% | 59 | 82% | 69 | 100% |
| Positive | 28 | 33% | 13 | 18% | 0 | 0% |
| BRCA1 mutation | ||||||
| BRCA1 mutation | 16 | 19% | 17 | 24% | 7 | 10% |
| No mutation | 19 | 23% | 44 | 61% | 0 | 0% |
| Unknown | 49 | 58% | 11 | 15% | 62 | 90% |
| BRCA1like status aCGH | ||||||
| BRCA1-like | 37 | 44% | 40 | 56% | 50 | 72% |
| Sporadic-like | 47 | 56% | 32 | 44% | 19 | 28% |
aCGH, array Comparative Genomic Hybridisation.